9M PREMARKET VOL AND RISING, HOLD FOR GOLD GENTS

Currently no walls on this thing, it's trading freely with market now. Shall fly past $6 with it's real valuations

Volume looking good, next stop .30c

push it push it real good uh uhh uhh uhh uhuhuhuhuh

Resistance broke at .20c cheer's mates!
.10c NASDAQ rule compliant ✅
Ph 3 data - forthcoming
$1 NASDAQ requirement by 8/24 - 21% there
2024 filing of the NDA remains on track 💪🏼

lowest volume morning in a month.... buy when its ugly

Over the past 30 days, the average Off Exchange & Dark Pool volume has been 60.28%.

LEVEL 2 ACTIVITY DEAD ALL EYES GLUED TO WEBSITE FOR ABSTRACT TITLE MENTION OR ANYTHING RELATED TO NAPO

ITS COMING ONLY A MATTER OF TIME THE SHIT IS DUE TODAY

I REPEAT, NOT EVERYTHING HAS BEEN UPDATED AS OF YET

DONT PANIC

APRIL 24, 2024 at 10:00 AM ET
Abstract Titles, including LBAs, Posted on meetings.asco.org

NOT ALL THINGS HAVE BEEN UPDATED AS OF 9;28AM

DONT PANIC

APRIL 24, 2024 at 10:00 AM ET
Abstract Titles, including LBAs, Posted on meetings.asco.org

APRIL 24, 2024 at 10:00 AM ET
Abstract Titles, including LBAs, Posted on meetings.asco.org

APRIL 24, 2024 at 10:00 AM ET
Abstract Titles, including LBAs, Posted on meetings.asco.org

0 SHARE AVAIL TO SHORT, 60% FEE ABSTRACT TITLES POSTED IN T MINUS 38 MINUTES... TIK TOK TIK TOK

DATES TO KNOW

APRIL 24, 2024 at 10:00 AM ET
Abstract Titles, including LBAs, Posted on meetings.asco.org

APRIL 24, 2024
Early Registration Deadline

MAY 13, 2024
Oral Abstract presentation slide deadline. Materials must be uploaded to ASCO's Speaker Center Website

MAY 20, 2024
Poster and Rapid Oral Abstract presentation presentation materials (slides and/or posters). Materials must be uploaded to ASCO's Speaker Center Website

MAY 23, 2024 at 5PM et
Majority of abstracts are released on asco.org/abstracts (Late-breaking Abstracts will be released at 7:00 AM CT on their day of presentation at the meeting)

MAY 31 - JUNE 4, 2024
ASCO Annual Meeting (Chicago, IL)

People are missing key facts here, the Napo pharmas abstract gets either accepted tomorrow or not for the presentation at it's booth for the conference in June. They already have a booth#, this is their first time presenting, they will be presenting near ImmunityBio, and among top billion dollar companies. look it up on my previous posts. Accepted means good news, they are going either way they have a BOOTH#. Do you think company wants to present TOPLINE PH3 data in June with a stock price under $1? THINK!!!!!! 🧐🧐

Gap fill .26 then 50s then $1 this stock is going to fly

A company that is suffering might do that. That is not the case here. Shelf will be used for funding FDA timeline, shelf will not be used like your negativity suggests

You could literally throw yesterdays trading Action out the window that was a doozy. Wow I've never seen such a dump then escalate move like with today's action. Know what you own. I'm not selling all my shares on initial pump,holding half more than a year. After FDA approval this goes $25+, r/s will not be needed, the shelf offering yesterday will fund the rest of they way.

in the meantime this will pump and dump over a $1 after ph3 data, it might even go $5+ and stay there like ImmunityBio, which is another company presenting at the conference right next to us.

Play it smart boys.

Check out the booth layouts and whos all around Napo at the conference.

https://events.jspargo.com/ASCO24/Public/Eventmap.aspx?EventId=776&MapID=990&MapItBoothID=1002766&MapItBooth=29138

Wow, missed the action while driving. This is great news. Shelf offering way better than public but there is some public in the file. Most is shelf though. Someone knows something and expects price to skyrocket 🚀🚀🚀🚀

sell now or forever hold your peace ;)

panic sell attack

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care

https://ons.confex.com/ons/2024/meetingapp.cgi/Session/5984

.20c incoming!

hahah so much volume that the borrow rate fee went to N/A 😂

ENTIRE market is bleeding and jaguar health is about to capture so much marketcap muhahahahaha

You don't hire people in top exec positions if you don't have a job for them. What's her job? In-liscensing.

In-licensing refers to the process where a company (the licensee) acquires the rights to a product, technology, or intellectual property from another organization (the licensor). This can include rights to develop, manufacture, and market a particular pharmaceutical product. In-licensing allows the licensee to expand its product portfolio, access innovative technologies, and enter new markets without having to develop the product or technology in-house.

After we take our gains in the double digits, we shall roll them into $SHIB Shiba Inu coin will be the next .01c crypto IMO not financial advice

The PLOS dog study was nonetheless more proof in the pudding. P VALUE WAS FANTASTIC 😊

Significantly more patients receiving crofelemer 125 mg achieved clinical response versus placebo (17.6% vs 8.0%; one-sided, P = .01). Crofelemer 125 mg resulted in a greater change from baseline in number of daily watery bowel movements (P = .04) and daily stool consistency score (P = .02) versus placebo. During the placebo-free extension phase, percentages of weekly responders ranged from 40% to 56% at weeks 11 to 24. Crofelemer was minimally absorbed, well tolerated, did not negatively impact clinical immune parameters, and had a safety profile comparable to placebo.

Conclusions: In HIV-seropositive patients taking stable antiretroviral therapy, crofelemer provided significant improvement in diarrhea with a favorable safety profile.

Lambo not my taste, I'm more of a nismo fan. Gtr all the way.

Don't believe the bears anywhere. Stick to the plan. $1 first, then it's ballgame. The ceiling is currently $9 when this reverse split last that's what it ran too.

In a clinical study known as the ADVENT trial, 374 adults living with HIV on antiretroviral therapy (ART) who had been experiencing noninfectious diarrhea for at least 1 month were given either 125 mg of Mytesi twice a day or a placebo (sugar pill).1 The study looked at how effective treatment was in an ethnically diverse patient population, comprised predominantly of male long-term survivors (LTSs).*

*LTS is a person living with HIV for >10 years.

if my calculations are correct we should be at .75c+ the fact of matter is the dark pool shorts are so fkd it's not even funny. I called my broker buddy today in NY, he ran behind scenes found some shit out for me. The FTDs are going to be so high for April it's not even funny..... The dark pool shorts are trading half the float daily and getting percentages of them stuck in there and they have to long to not lose money. It's coming to the tip of the iceberg. Like if you take a very tiny glass and pour a 5 gallon bucket of water in it. The tiny glass is about to go flying, water everywhere, and everything under water, including the fraudulent brokers allowing it to happen. The stock price might pull a GameStop. Not financial advice. Ph3 data, the orphan drug designation, the other 5 indications, this drug is going to capture billions in marketcap.

Catherine Collins drug up Vibrant Gastro for Jaguar Heath 🐆 🚀

💥blast offffffffffff

Total Short Volume Reported
2024-04-17 44,149,777
2024-04-16 262,453,926
2024-04-15 55,653,114

"We are confident that her extensive commercial and business development experience will prove invaluable as we continue to evolve and execute our in-licensing growth strategy in the areas of cancer and GI supportive care, initiate the commercial launch of Gelclair, and focus on our ongoing mission to serve patients in need around the globe."

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

https://finance.yahoo.com/news/jaguar-health-appoints-biopharmaceutical-industry-123000571.html?

yeah the one i'm about to take at work